Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""O'Byrne, K. J."" wg kryterium: Autor


Wyświetlanie 1-9 z 9
Tytuł :
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.
Autorzy :
Sharma RA; Department of Radiotherapy, Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey London, SM2 5PT, UK. />Steward WP
Daines CA
Knight RD
O'Byrne KJ
Dalgleish AG
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2006 Sep; Vol. 42 (14), pp. 2318-25. Date of Electronic Publication: 2006 Aug 08.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*adverse effects
Immunologic Factors/*adverse effects
Neoplasms/*drug therapy
Thalidomide/*analogs & derivatives
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Cohort Studies ; Dose-Response Relationship, Drug ; Female ; Humans ; Immunologic Factors/administration & dosage ; Lenalidomide ; Male ; Middle Aged ; Thalidomide/administration & dosage ; Thalidomide/adverse effects
Czasopismo naukowe
Tytuł :
Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.
Autorzy :
Sharma RA; University Department of Oncology, Leicester Royal Infirmary, UK. />Eatock MM
Twelves CJ
Brown G
McLelland HR
Clayton KT
O'Byrne KJ
Moyses C
Carmichael J
Steward WP
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2001 Sep; Vol. 48 (3), pp. 197-201.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Fluorouracil*/*analogs & derivatives
Antineoplastic Agents/*pharmacokinetics
Fluoresceins/*pharmacokinetics
Liver/*metabolism
Neoplasms/*metabolism
Administration, Oral ; Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Area Under Curve ; Biological Availability ; Drug Administration Schedule ; Female ; Fluoresceins/administration & dosage ; Humans ; Infusions, Intravenous ; Male ; Maximum Tolerated Dose ; Metabolic Clearance Rate ; Middle Aged ; Neoplasms/drug therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Autorzy :
Braybrooke JP; Department of Urology, Churchill Hospital, Oxford, United Kingdom.
O'Byrne KJ
Propper DJ
Blann A
Saunders M
Dobbs N
Han C
Woodhull J
Mitchell K
Crew J
Smith K
Stephens R
Ganesan TS
Talbot DC
Harris AL
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2000 Dec; Vol. 6 (12), pp. 4697-704.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Neovascularization, Pathologic*
Topoisomerase II Inhibitors*
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Razoxane/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Biomarkers ; Carcinoma, Renal Cell/blood ; Disease-Free Survival ; E-Selectin/blood ; Endothelial Growth Factors/blood ; Endothelial Growth Factors/urine ; Female ; Fibroblast Growth Factor 2/blood ; Fibroblast Growth Factor 2/urine ; Humans ; Kidney Neoplasms/blood ; Lymphokines/blood ; Lymphokines/urine ; Male ; Middle Aged ; Razoxane/adverse effects ; Receptors, Cell Surface/blood ; Receptors, Urokinase Plasminogen Activator ; Time Factors ; Treatment Outcome ; Vascular Cell Adhesion Molecule-1/blood ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors ; von Willebrand Factor/biosynthesis
Czasopismo naukowe
Tytuł :
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
Autorzy :
O'Byrne KJ; Imperial Cancer Research Fund Medical Oncology Unit, Churchill Hospital, Oxford, UK.
Dobbs N
Propper DJ
Braybrooke JP
Koukourakis MI
Mitchell K
Woodhull J
Talbot DC
Schally AV
Harris AL
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 1999 Mar; Vol. 79 (9-10), pp. 1413-8.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Breast Neoplasms/*drug therapy
Somatostatin/*analogs & derivatives
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Breast Neoplasms/blood ; Breast Neoplasms/pathology ; Disease Progression ; Female ; Humans ; Insulin-Like Growth Factor I/metabolism ; Middle Aged ; Neoplasm Staging ; Prolactin/blood ; Somatostatin/administration & dosage ; Somatostatin/adverse effects
Czasopismo naukowe
Tytuł :
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Autorzy :
Macaulay VM; Imperial Cancer Research Fund, Medical Oncology Unit, Churchill Hospital, Oxford, United Kingdom.
O'Byrne KJ
Saunders MP
Braybrooke JP
Long L
Gleeson F
Mason CS
Harris AL
Brown P
Talbot DC
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 1999 Mar; Vol. 5 (3), pp. 513-20.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Matrix Metalloproteinase Inhibitors*
Antineoplastic Agents/*therapeutic use
Enzyme Inhibitors/*therapeutic use
Phenylalanine/*analogs & derivatives
Pleural Effusion, Malignant/*drug therapy
Thiophenes/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/pharmacokinetics ; Female ; Humans ; Male ; Matrix Metalloproteinase 1 ; Middle Aged ; Outcome Assessment, Health Care ; Phenylalanine/adverse effects ; Phenylalanine/pharmacokinetics ; Phenylalanine/therapeutic use ; Pleural Effusion, Malignant/metabolism ; Thiophenes/adverse effects ; Thiophenes/pharmacokinetics
Czasopismo naukowe
Tytuł :
A phase II study of bryostatin 1 in metastatic malignant melanoma.
Autorzy :
Propper DJ; ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK.
Macaulay V
O'Byrne KJ
Braybrooke JP
Wilner SM
Ganesan TS
Talbot DC
Harris AL
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 1998 Nov; Vol. 78 (10), pp. 1337-41.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Lactones/*therapeutic use
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Bryostatins ; Disease Progression ; Drug Resistance, Neoplasm ; Female ; Humans ; Lactones/administration & dosage ; Lactones/adverse effects ; Macrolides ; Male ; Melanoma/pathology ; Middle Aged ; Skin Neoplasms/pathology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase II study of liarozole in advanced non-small cell lung cancer.
Autorzy :
O'Byrne KJ; Imperial Cancer Research Fund Medical Oncology Unit, Oxford Radcliffe Hospital, U.K.
Han C
Mitchell K
Lane D
Carmichael J
Harris AL
Talbot DC
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 1998 Aug; Vol. 34 (9), pp. 1463-6.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Imidazoles/*administration & dosage
Lung Neoplasms/*drug therapy
Administration, Oral ; Aged ; Antineoplastic Agents/adverse effects ; Female ; Humans ; Imidazoles/adverse effects ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors.
Autorzy :
Saunders MP; Imperial Cancer Research Fund, Medical Oncology Unit, Churchill Hospital, Oxford, United Kingdom.
Salisbury AJ
O'Byrne KJ
Long L
Whitehouse RM
Talbot DC
Mawer EB
Harris AL
Pokaż więcej
Źródło :
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 1997 Dec; Vol. 82 (12), pp. 4044-8.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
8-Bromo Cyclic Adenosine Monophosphate/*analogs & derivatives
Antineoplastic Agents/*adverse effects
Cyclic AMP/*analogs & derivatives
Hypercalcemia/*chemically induced
Neoplasms/*metabolism
Vitamin D/*analogs & derivatives
8-Bromo Cyclic Adenosine Monophosphate/administration & dosage ; 8-Bromo Cyclic Adenosine Monophosphate/adverse effects ; 8-Bromo Cyclic Adenosine Monophosphate/therapeutic use ; Adolescent ; Adult ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Dose-Response Relationship, Drug ; Feasibility Studies ; Humans ; Parathyroid Hormone/blood ; Vitamin D/biosynthesis
Czasopismo naukowe
    Wyświetlanie 1-9 z 9

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies